Advertisement

Topics

EhmetDx inks deal for the world's first self-shielded radiotherapy device

08:16 EDT 26 Sep 2017 | PR Newswire

PLYMOUTH, Mich., Sept. 26, 2017 /PRNewswire/ -- EhmetDx, a Michigan based medical device company has executed an agreement with Orbital Therapy of Waltham, MA. acquiring exclusive rights to its highly anticipated radiotherapy device the MammoKnife. The patented device was conceived by Alan Sliski who co-founded both PhotoElectron (now Zeiss) and Still River Systems (now Mevion Medical Systems). This device is the world's first self-shielded radiotherapy treatment dedicated to breast cancer. Without the need for additional costly shielding or bunkers, the MammoKnife can be housed in any treatment center or medical office allowing for a broader reach to patients in need.

"The MammoKnife has the advantage of applying the best in current radiotherapy solutions in a reconfigured enclosure that eliminates the need for a traditional vault, and has the potential to dramatically spare surrounding healthy tissue from unwanted radiation," said Alan Sliski.

Alan remains a mentor in at Harvard University's Rowland Institute. He joins the EhmetDx team adding therapeutic wisdom to its core strength in diagnostics. His development of the MammoKnife is the culmination of decades of experience in pioneering innovative radiotherapy devices.

"Nearly 1 million women worldwide will be diagnosed this year, including 250 thousand in the United States alone. It is important for us to take the lead in finding new ways to treat that have better outcomes and keep costs to a minimum," said Michael Teicher, CEO of EhmetDx.

About EhmetDx: EhmetDxis a medical device company based out of Plymouth, MI. Its team has a long history in the commercialization of medical imaging and particle beam therapy instruments with collective revenue in billions of dollars. The EhmetDx team is composed of a wide spectrum of skilled professionals with one common vision: to bring a distinguished sense of execution to the medical device industry. EhmetDx is exhibiting at The American Society of Radiation Oncology's (ASTRO) 2017 Annual Meeting in San Diego September 24th-26th Booth #2957. Follow EhmetDx on Facebook and LinkedIn for the company's latest news and events or visit www.ehmetdx.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/ehmetdx-inks-deal-for-the-worlds-first-self-shielded-radiotherapy-device-300526017.html

SOURCE EhmetDx

NEXT ARTICLE

More From BioPortfolio on "EhmetDx inks deal for the world's first self-shielded radiotherapy device"

Quick Search
Advertisement
 

Relevant Topics

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...